scholarly journals OSTEOSARCOMA HAS NOT BECOME ATTENTION TO SOCIETY PROFILE OF OSTEOSARCOMA PATIENTS AT DR. SOETOMO GENERAL HOSPITAL SURABAYA “A RETROSPECTIVE STUDY”

2019 ◽  
Vol 7 (1) ◽  
pp. 20
Author(s):  
Ferdiansyah Mahyudin ◽  
Mouli Edward ◽  
Muhammad Hardian Basuki ◽  
Yunus Abdul Bari ◽  
Yesa Suwandani
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
General Hospital ◽  
Detection Rate ◽  
Survival Rates ◽  
Bone Neoplasm ◽  
High Rate ◽  
Osteosarcoma Patient ◽  
Tumor Patient ◽  
Patient Database

Background: Osteosarcoma is the most common bone neoplasm found in the community but evaluation osteosarcoma cases in RSUD Dr. Soetomo has not been updated since 1995.Purpose: This study o osteosarcoma patient characteristic as well as therapy at Dr. Soetomo General Hospital in 2007 to 2016. It expects to show survival rates of osteosarcoma patient, so it can be a reference for searching the problems in the treatment of osteosarcoma cases and helps to decide treatment for osteosarcoma.Research Methods: Descriptive retrospective study, conducted on osteosarcoma patients at Dr. Soetomo General Hospital during 2007-2016 periods. Data were obtained from Ortho tumor patient database, and contacting them by phone or home visit.Results: Osteosarcoma patients was found mostly in 2015, while the least in 2008, with trend increasing by time. Majority of the patients came with advanced stage. Osteosarcoma treated mostly by amputation, either with or without chemotherapy. The survival rate in the first, second, or the fifth year was found lower than other references. Most common cause of mortality was the metastasis.Conclusion: Awareness of the society about the cancer sign of cancer and desire to use medical treatment as a priority is still low. This causes a low early detection rate of osteosarcoma and a high rate of metastatic cases because of inappropriate early treatment. Further socialization and increased awareness of medics about the suspicion of osteosarcoma are needed to improve the success rate of treatment as well as the survival rate.

scholarly journals Survival Rate of 1008 Short Dental Implants with 21 Months of Average Follow-Up: A Retrospective Study

2020 ◽  
Vol 9 (12) ◽  
pp. 3943
Author(s):  
João Caramês ◽  
Ana Catarina Pinto ◽  
Gonçalo Caramês ◽  
Helena Francisco ◽  
Joana Fialho ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Dental Implants ◽  
Cox Regression ◽  
Survival Rates ◽  
High Survival ◽  
Implant Survival ◽  
Posterior Maxilla ◽  
Clinical Records

This retrospective study evaluated the survival rate of short, sandblasted acid-etched surfaced implants with 6 and 8 mm lengths with at least 120 days of follow-up. Data concerning patient, implant and surgery characteristics were retrieved from clinical records. Sandblasted and acid-etched (SLA)-surfaced tissue-level 6 mm (TL6) or 8 mm (TL8) implants or bone-level tapered 8 mm (BLT8) implants were used. Absolute and relative frequency distributions were calculated for qualitative variables and mean values and standard deviations for quantitative variables. A Cox regression model was performed to verify whether type, length and/or width influence the implant survival. The cumulative implant survival rate was assessed by time-to-event analyses (Kaplan–Meier estimator). In all, 513 patients with a mean age of 58.00 ± 12.44 years received 1008 dental implants with a mean follow-up of 21.57 ± 10.77 months. Most implants (78.17%) presented a 4.1 mm diameter, and the most frequent indication was a partially edentulous arch (44.15%). The most frequent locations were the posterior mandible (53.97%) and the posterior maxilla (31.55%). No significant differences were found in survival rates between groups of type, length and width of implant with the cumulative rate being 97.7% ± 0.5%. Within the limitations of this study, the evaluated short implants are a predictable option with high survival rates during the follow-up without statistical differences between the appraised types, lengths and widths.

scholarly journals The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5369-5369
Author(s):  
Khalid Nasser Al Hashmi ◽  
Kamla Alwahaibi ◽  
Murtadha K. Al-Khabori
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Tertiary Care ◽  
Survival Rates ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Lymph Node Enlargement ◽  
Tertiary Care Centers

Abstract Background and Objectives Hodgkin's lymphoma (HL) is a B cell lymphoma characterized by the presence of Reed-Sternberg cells. HL comprises 1% of all cancer cases and 14% of all lymphoma cases. The clinical presentation and survival rate of these patients have not been described in Oman. We, therefore, aimed to describe the clinical characteristics and survival rate of patients with classical Hodgkin's lymphoma. Methods This is a retrospective study that was conducted in a tertiary care centers in the Sultanate of Oman. All Omani adults with histopathological confirmed diagnosis of classical Hodgkin's lymphoma from 2000 to 2016 were included in this study. The demographic, clinical, and survival rate were recorded and analyzed. Results A total of 273 patients (45 % females and 55% males, mean age 32) fulfilled the inclusion criteria with histopathological confirmed diagnosis of classical Hodgkin's lymphoma. The commonest presenting feature was lymph node enlargement (83%); followed by fever (48%). The most common classical HL histological subtype was nodular sclerosing HL (NSHL) (71%). The most common stage was II 34%. The most common chemotherapy regimen used as the first line was doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) (89%). Five and 10-year survival rates were 93.8 % and 99.2%, respectively. Conclusions This is the first study that demonstrates the demographic, clinical and survival rate of HL patients in Oman, and provides a general picture of the HL patients in our country. Disclosures No relevant conflicts of interest to declare.

Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma：A retrospective study

2021 ◽  
Author(s):  
Xiaofei Wang ◽  
Shu Chen ◽  
Huaqiang Bi ◽  
Feng Xia ◽  
Kai Feng ◽  
...  
Keyword(s):  
Overall Survival ◽  
Retrospective Study ◽  
Radiofrequency Ablation ◽  
Survival Rate ◽  
Combination Therapy ◽  
Multivariate Analyses ◽  
Survival Rates ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Tumor Number

Abstract Background: The aim of this study was to evaluate whether combined therapy with PD-1 blockade (anti-PD-1) and radiofrequency ablation (RFA) was superior to RFA monotherapy for recurrent hepatocellular carcinoma (HCC).METHODS: A total of 127 patients who underwent anti-PD-1 plus RFA treatment (n = 41) or RFA alone treatment (n = 86) for recurrent HCC were enrolled in this retrospective study. Clinical data including post-RFA HCC recurrence (the primary end point), overall survival (OS) (the secondary end point), adverse events and toxic effects were retrospectively analyzed.RESULTS: The 1-year recurrence-free survival rates for the anti-PD-1 plus RFA and RFA groups were 36.6% and 16.3%, respectively. The corresponding overall survival rates for the two groups were 95.1% and 74.4%, respectively. There were statistically significant differences between the two groups in recurrence-free survival rate (P = 0.002) or overall survival rate (P = 0.008). Tumor number, TNM stage and anti-PD-1 treatment were demonstrated to be important factors associated with 1-year recurrence-free survival probability by univariate and multivariate analyses. Univariate and multivariate analyses demonstrated that tumor number, TNM stage and anti-PD-1 treatment were significant prognostic factors for OS. RFA treatment-related adverse events were pleural effusion requiring drainage and mild or moderate increase in body temperature. Grade 3 or higher events related to anti-PD-1 treatment occurred in 12.8% (6) patients and were infrequent.CONCLUSIONS: Combination therapy of anti-PD-1 plus RFA was superior to RFA alone in improving survival for recurrent HCC.

scholarly journals Post-warming survival rates and clinical outcomes of human cleavage stage embryos vitrified/warmed using CryoTouch and Cryotop methods

2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Somayeh Keshavarzi ◽  
Azadeh Dokht Eftekhari ◽  
Hajar Vahabzadeh ◽  
Marzieh Mehrafza ◽  
Robabeh Taheripanah ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Clinical Outcomes ◽  
Live Birth ◽  
Survival Rates ◽  
Implantation Rate ◽  
Clinical Pregnancy ◽  
Human Embryos ◽  
Cleavage Stage ◽  
Embryo Survival

Abstract Background Vitrification has become the method of choice for cryopreservation of human embryos and gametes. There are multiple commercial media, containing different combinations and concentrations of cryoprotectants, available for vitrification and warming procedures. The aim of this retrospective study was to compare post-warming survival rate and clinical outcomes of cleavage stage embryos vitrified/warmed using two different commercial methods (CryoTouch and Cryotop) during intracytoplasmic sperm injection/frozen embryo transfer (ICSI/FET) cycles. This retrospective study evaluated a total of 173 FET cycles performed on 446 warmed cleavage stage embryos between January 2018 and December 2020. Post-warming embryo survival rate and clinical outcomes including clinical pregnancy, implantation, and live birth rates were calculated. Results The results showed no significant differences between two groups in terms of post-warming survival rate (p value = 0.5020), clinical pregnancy rate (p value = 0.7411), implantation rate (p value = 0.4694), and live birth rate (p value = 0.5737). Conclusions Collectively, high successful rates were observed in outcomes of vitrified/warmed cleavage stage embryos using both CryoTouch and Cryotop commercial methods.

scholarly journals Porous tantalum rod implantation is associated with low survival rates in patients with type C2 osteonecrosis of the femoral head but has no effect on the clinical outcome of conversion total hip arthroplasty: a retrospective study with an average 8-year follow-up

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Mincong He ◽  
Qiushi Wei ◽  
Zhenqiu Chen ◽  
Fan Yang ◽  
Xiaojun Chen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Femoral Head ◽  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Survival Rates ◽  
Stage Ii ◽  
Stage Iii ◽  
Porous Tantalum

Abstract Background Our study aimed to investigate the clinical outcomes and survival rates following porous tantalum rod surgery (PTRS) and conversion total hip arthroplasty (THA) subsequent to failed PTRS. Methods A total of 38 subjects (40 hips) with osteonecrosis of the femoral head (ONFH) were included in this retrospective study between January 2008 and December 2011. All subjects were evaluated before surgery by using the Association Research Circulation Osseous (ARCO) classification system, the Japan Investigation Committee (JIC) classification and the Harris hip score (HHS). The endpoint of this study was set as final follow-up (including the survival time of PTRS and conversion THA). The rates of radiological progression were also evaluated. Patients who received conversion THA were further followed and compared to a control group of 58 patients with ONFH who underwent primary THA. Results The mean follow-up time was 120.7 ± 9.2 (range, 104–143) months, and the overall survival rate was 75% at 96 months (ARCO stage II: 81.5%; stage III: 38.5%; JIC type C1: 83.3%; C2: 30%). The HHS before surgery was 59 (55–61), in contrast to 94 (91–96) at 96 months follow-up (P < 0.01). HHS in stage III show a significant poorer result compared to stage II at 24 months. HHS in Type C2 group show no significant difference compared to HHS before surgery at 24 and 60 months follow up (P = 0.91, P = 0.30). Twelve hips requiring secondary THA were followed for 66.9 ± 31.7 months, and control hips that underwent primary THA was followed for 75.4 ± 14.9 months. The HHS in the conversion group was 89 (86–93) and that in the primary THA group was 92 (79–95, P = 0.09) at the 5-year follow-up. Conclusion In the mid-term follow-up, porous tantalum implants showed an encouraging survival rate in symptomatic patients in early stages (ARCO stage II) or with limited necrotic lesions (JIC type C1). In addition, our results did not demonstrated any difference between primary THA and conversion THA.

Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

1998 ◽  
Vol 16 (6) ◽  
pp. 2007-2017 ◽  
Author(s):  
H M Katzenstein ◽  
L C Bowman ◽  
G M Brodeur ◽  
P S Thorner ◽  
V V Joshi ◽  
...  
Keyword(s):  
Survival Rate ◽  
Pediatric Oncology ◽  
Tumor Biology ◽  
Survival Rates ◽  
Prognostic Significance ◽  
Age At Diagnosis ◽  
High Rate ◽  
Oncology Group ◽  
Pediatric Oncology Group ◽  
Stage D

PURPOSE Although a high rate of spontaneous regression is observed in infants with stage D(S) neuroblastoma (NB), survival is not uniform. To determine the prognostic relevance of age at diagnosis, therapy, and tumor biology in infants with stage D(S) NB, we reviewed the Pediatric Oncology Group (POG) experience. PATIENTS AND METHODS A review of patients diagnosed with stage D(S) NB registered on POG protocols was performed. Survival according to age at diagnosis, treatment, and tumor biology was determined. RESULTS Between 1987 and 1996, 110 infants with stage D(S) NB had an estimated 3-year survival rate of 85% +/- 4%; survival rate was 71% +/- 8% for infants 2 months of age or younger, and 68% +/- 12%, 44% +/- 33%, and 33% +/- 19% for patients with diploid, MYCN-amplified, and unfavorable histology tumors, respectively. Survival rates were similar for patients who received adjuvant chemotherapy versus those who did not (82% +/- 5% v 93% +/- 6%, respectively; P = .187). Furthermore, there was no statistical difference in survival rate for patients who underwent complete resection of their primary tumor compared with those who underwent partial resection or biopsy only (90% +/- 5% v 78% +/- 7%, respectively; P = .083). CONCLUSION Our review confirmed that the survival of infants with stage D(S) NB is excellent. However, subsets of patients with poor prognosis can be identified by young age and unfavorable biologic factors. More effective therapy is needed for the group of stage D(S) infants who show unfavorable clinical and biologic features.

Does the number of embryos loaded on a single cryo-carrier affect post-vitrification survival rate?

Zygote ◽  
2020 ◽  
pp. 1-5
Author(s):  
Adva Aizer ◽  
Meirav Noach-Hirsh ◽  
Olga Dratviman-Storobinsky ◽  
Jigal Haas ◽  
Raoul Orvieto
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Survival Rates ◽  
Blastocyst Stage ◽  
Optimum Number ◽  
Cleavage Stage ◽  
Cell Stage ◽  
Embryo Survival ◽  
Intact Embryo

Abstract Background: We aimed to assess whether the survival rate of embryos is influenced by the number of embryos/oocytes loaded on a single cryo-carrier during vitrification. Methods: This was a retrospective study that included 974 patients who underwent thawing of 1896 embryo-warming cycles between September 2016 and January 2020. A distinct analysis was made for cleavage stage embryos (2–10-cell stage) and blastocysts. For vitrification, embryos were placed in a Cryotop™ open device using a SAGE vitrification kit following the manufacturer’s instructions. Warming was carried using a SAGE warming vitrification kit according the manufacturer’s instructions. Results: Total post-vitrification survival rates of embryos at the cleavage stage or blastocyst stage was 94.8%. At the cleavage stage, cryo-preserving three embryos per single cryo-carrier gave the highest full intact embryo survival rate (91.5%) compared with one or two embryo(s) per single cryo-carrier (85.7%, P < 0.0002 and 87.3%, P < 0.004). Conversely, post warmed full intact blastocyst survival rate for two blastocysts was significantly lower compared with one blastocyst (76.7% vs. 87.9%, P < 0.0193) per single cryo-carrier. Conclusion: Post-thawing survival rate following vitrification is affected by the number of embryos per single cryo-carrier undergoing the vitrification equilibration phase, with the optimum number of three cleaved embryos or one blastocyst per single cryo-carrier. Further studies are required to determine the optimum number of cleaved embryos or blastocysts that should be loaded onto a single cryo-carrier vitrification device.

Digital Replantations: Comparison Veins Anastomoses first versus Arteries Anastomoses first

2021 ◽  
Vol 53 (05) ◽  
pp. 488-493
Author(s):  
Andrea Leti Acciaro ◽  
Giulia Colzani ◽  
Norman Della Rosa ◽  
Marta Starnoni ◽  
Roberto Adani
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Clinical Outcome ◽  
Grip Strength ◽  
Survival Rates ◽  
Adult Patients ◽  
Active Motion ◽  
Significant Difference ◽  
Total Active Motion ◽  
Digital Replantation

Abstract Purpose This retrospective study analyses the effect performing veins anastomoses before arteries anastomoses in digital replantation. Patients and methods 38 adult patients with replantation of 12 thumbs and 39 fingers, in whom the veins anastomoses were performed prior to the arteries anastomoses, were compared with 29 patients with replantation of 9 thumbs and 30 fingers, in whom the arteries anastomoses were done first, with respect to the survival rate, total active motion, grip strength, and duration of the replantation. Results There was no significant difference between the two groups with respect to the survival rates, total active motion, and grip strength, while the duration of the replantation was significantly shorter in patients, in whom the veins anastomoses were performed prior to the arteries anastomoses (2 hours and 50 minutes versus 3 hours and 42 minutes; p < 0.001). Conclusion Performing veins anastomoses before arteries anastomoses in digital replantations reduces the replantation time significantly without influencing the survival rate and the clinical outcome.

scholarly journals Epidemiology cancer of the cervix, uterine body and ovary in Republic of Srpska // Epidemiloška situacija raka grlića materice, tijela materice i jajnika u Republici Srpskoj

2018 ◽  
Vol 5 (1) ◽  
pp. 33
Author(s):  
Darijana Antonić
Keyword(s):  
Survival Rate ◽  
Survival Rates ◽  
Cervix Cancer ◽  
High Rate ◽  
Cancer Death ◽  
The Republic ◽  
Cancer Of The Cervix ◽  
Uterine Body

Introduction: Cancer of the cervix, uterine body and ovary together with cancer of the breast account more the 1/3 female’s cancer cases in the Republic of Srpska. Cancer of the cervix, uterine body and ovary are responsible for 13.82% cancer death females, and the leading cause of cancer death females is cancer of the ovary (5.62%). Sources and methods: Mediana age diagnosed new cases of the cervix cancer is 47 years and uterin body and ovary the median age is in sixties. Relationship beetwen age-standardized rate prevalence (world) and age-standardized rate incidence cancer of the cervix, uterin body and ovary and confirm that high rate of incidence determines high rate of prevalence, this correlation is positive and relationship statistical significant (p<0.01). Relative five years survival rates of the cervix and uterin body cancer are over 80% and cancer of the ovary have almost 2.5 times lower relative five years survival rate.

scholarly journals Surgical and Prosthetic Outcomes of 967 Implants Under Immediate or Delayed Loading in Full-Arch Rehabilitation: a Retrospective Study With up To 5 Years of Follow-Up

2021 ◽  
Vol 24 (3) ◽  
Author(s):  
Geninho Thome ◽  
Waleska Caldas ◽  
Camila Pereira Vianna ◽  
Carolina Accorsi Cartelli ◽  
Larissa Carvalho Trojan
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Treatment Time ◽  
Survival Rates ◽  
Immediate Loading ◽  
Implant Survival ◽  
Prosthesis Survival ◽  
Implant Survival Rate ◽  
Clinical Records

Objective: The aim of this study was to evaluate implant and prosthesis survival rates in full-arch rehabilitation supported by implants with platform-switched Morse taper connection submitted to immediate or delayed loading, after up to 5 years of follow-up. Material and Methods: Data was retrospectively collected from clinical records of patients who were treated by means of implant-supported full-arch rehabilitation. Survival rates of implants and prostheses were evaluated according to immediate or delayed loading. Results: The sample comprised 967 implants. Of those, 627 were submitted to immediate loading (IL) while 340 to delayed loading (DL). After a follow-up period of up to 5 years, the implant survival rate for IL was of 99.7% (622/627 implants) and 97.2% (333/340 implants) for DL. The overall implant survival rate was 98.8% (955/967 implants). Prosthesis survival rate was 100% (N = 178) for both groups. Significantly more implants in the DL group presented bone loss (p > 0.01), either greater or lower than 2 mm, during the follow-up period. Conclusion: Within their limits, the present results suggest that full-arch rehabilitation with platform-switched Morse taper connection implants can lead to surgical and prosthetic predictable outcomes. Moreover, immediate loading protocol seems to be a good option for the rehabilitation of fully edentulous patients, as it involves a shorter treatment time, which may lead to greater patient satisfaction.   Keywords Dental implants; Rehabilitation; Survival rate; Retrospective study.

Sign in / Sign up

Export Citation Format

Share Document